



Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Canon Ltd (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.



INTRODUCTION






CANONIC
CULTIVATED BY SCIENCE

OUR VISION

Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect

Global Cannabis Market

Legal Cannabis Worldwide: \$46.8 Billion in 2025



Source: Arcview Market Research/BDSA

Market Challenges



STABILITY

Substantial variations within varieties produce inconsistent products and therefore, inconsistent results



YIELD

Low yield of active compounds affects income per sq foot



SPECIFICITY

Significant knowledge gap prevents matching active compounds to medical indications

The opportunity : With state-of-the-art plant genomic expertise, major market challenges can be solved

The opportunity

From Plant Genetics – To Medical Cannabis Products

Plant genetics know-how is the basis for development of **premium Cannabis varieties**



Premium varieties can lead to **novel medical Cannabis products** addressing market challenges





PRODUCTS



Variety Families Under Development

MetaYield⁺

Stable enhancement of **total plant** compounds

Focus on **agronomic** and **consumer** traits



Increased active compounds

[e.g. Increased trichomes prevalence]



Optimize consumer traits

[e.g. inflorescence size, density, scent]

First products in the market

Precise⁺

Stable enhancement of **specific active** compounds

Focus on **therapeutic** traits



Medical indication focus

[e.g. Pain & Inflammation]



Compound profile focus

[e.g. CBG, CBC]

Next generation products

MetaYield⁺ Varieties – The G-nnovation series

Now available in more than 70 pharmacies in Israel

Product 1: G150



IMC* category T15C3



18 % THC



High consumer rank

Product 2: G200



IMC* category T20C4



21 % THC



High consumer rank

*IMC- Israel Medical Cannabis agency in the Ministry of Health

Precise⁺: Medical indication focus



PRODUCT 1 (under development)

-  **Indication:** Inflammation
-  **Pre-clinical study:** Hadassah medical center
-  **Status:** product development
-  **Expected launch:** 2023
-  **Target market size in 2023*:** Israel \$115M, EU \$300M



PRODUCT 2 (under development)






-  **Indication:** Pain
-  **Pre-clinical study:** Migal research center
-  **Status:** product development
-  **Expected launch:** 2023
-  **Target market size in 2023*:** Israel \$280 M, EU \$750M



*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.

Precise⁺: Specific compound profile

PRODUCT 3 (under development)

-  **Targeting specific compound profile**
-  **Pre-clinical study:** under evaluation
-  **Status:** product development



Collaboration With Tikun Olam-Cannbit

TIKUN^{OLAM}
MEDICAL CANNABIS
CANNBIT PHARMACEUTICALS LTD

A close-up photograph of a cannabis plant being examined under a microscope. The plant is positioned on the microscope's stage, and a bright light from the microscope's eyepiece illuminates it. The background is a warm, yellowish-green color. In the top left corner, there is a decorative pattern of white, hand-drawn circles and ovals of various sizes.

TECHNOLOGY

The Genomic Power – improving performance

The potential: Improving plant traits through advanced breeding

Example –

Corn is considered a leading commercial crop

Wild corn went through genetic changes before it became a commercial crop.

The challenge:

Connect genomic elements to traits

Shorten the development time

The opportunity => BIG DATA AND
COMPUTATIONAL BIOLOGY



When Data Meets Computational Biology



Computational Genomics

Combining deep scientific know-how with Big Data and AI technology to tailor the plant genetics for improvement of plant traits and development of unique cannabis products



Canonic proprietary database and assets

>1000 characterized lines
(>17.5*10⁶ data points)



Genotype



Phenotype



Chemotype



Pre-clinical

**Accumulated
assets**



Genetic bank
'Mother' plants,
seeds,
tissue culture



Genetic markers
For traits of interest
(e.g. active compounds)



**Diverse Breeding
populations**
Proprietary hybrids

Big Data & AI transforming Data to Know-how




Plant genomics
database with $> 10^9$
data points on > 200
plants



**Proprietary
Cannabis genomic &
chemical data** on $>$
1000 lines



**Pre-clinical
data**



Products




The genomic power – 20% increase in THC content

Developing next generation MetaYield⁺ products

By leveraging our unique proprietary know-how and database, within 12 months we have:

- Improved the target trait by 20%
- Reached 6-fold increase in number of cannabis lines with >20% THC content



Demonstrated Capabilities Along The Development Value Chain

Canonic holds computational genomics capabilities and the full plant infrastructure to execute



Large genetic & breeding collections



State of the art data collection tools



World-class computational genomics




Advanced-breeding facility



Fully equipped labs & tissue culture rooms



Certified Propagation farm






BUSINESS MODEL



Cannabis Value Chain

Seed to Sale Powered by Genomics



Canonic in the Cannabis Value Chain

Reduced time to market and higher profitability by leveraging our proprietary genomic expertise and outsourcing downstream elements of the value chain





SUMMARY



Team



Dr. Arnon Heyman
CEO



Tanya Damm Bokobza
EVP Business Development



Dr. Inbal Dangoor
VP R&D



Guy Adler
VP Product



Elena Huly
Marketing & Sales



Yonatan Wegman
Head Agronomist



Dr. Michi Brog
Plant Breeder



Dr. Haleli Sharir
Clinical Research Director

Directors and Advisory Board

Board of directors



Ofer Haviv

Chairman of the board
Evogene President & CEO



Raanan Cohen

Business strategy
Former CEO Koor Industries



Dorit Kreiner

Finance
Evogene CFO

Advisory board



Prof. Yossi Tam

Cannabinoid clinical research
Director, Multidisciplinary Center for
Cannabinoid Research of the Hebrew
University



Nirit Elyovich

Marketing strategy
Senior marketing specialist with
over 20 years of B2C experience



Omri Ofer

Pharmaceutical distribution
Former CEO Chemipal



Dr. Yariv Brotman


Plant metabolic pathways
Ben Gurion University & Max Planck
Institute of Molecular Plant Physiology



Shai Leviatov

Plant breeding
Commercial varieties breeding for
more than 30 years in top leading
multinational seeds companies

Company Milestones



Summary

- ❖ **Canonic's distinct market advantage** is in mapping, decoding and stabilizing cannabis genetics for better health.
- ❖ Canonic holds exclusive rights to Evogene's (NASDAQ, TASE: EVGN) state-of-the-art **computational genomics technology**, for product development for the Cannabis market segment.
- ❖ **Canonic's first two products, G-150 and G-200**, were launched in Israel in October 2021.
- ❖ Next generation products are expected to focus on 2 major medical indications, **pain and inflammation**, which represent > 60% of the medical market*.
- ❖ Canonic aims to enter the EU market during 2023.



*Company estimate, based on data published by Israeli Ministry of health regarding number of medical cannabis users in Israel



CANONIC

CULTIVATED by SCIENCE

THANK YOU